Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Formosa Biomedical Material Technology Corporation has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This prosecution is handled by 1 distinct examiner across 1 distinct art unit. The busiest examiner is TESKIN, FRED M, who has 1 pending office action. The company's current patent office activity is highly concentrated, with the current case being the sole active matter.
Because the portfolio involves only 1 distinct examiner and 1 distinct art unit, there is no internal data to compare examiner behavior or prosecution speed. Practitioners should focus their strategy on the specific preferences of TESKIN, FRED M. In the Biotechnology & Pharmaceuticals field, having only 1 pending office action means the company's current intellectual property trajectory is tied to the outcome of this single case. The involvement of 1 distinct art unit indicates that the company's current innovations are being evaluated within 1 specialized department, necessitating a focused approach to meet that unit's specific requirements.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TESKIN, FRED M | 1 | 89.6% | +7.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18582695 | Thermo-induced stimuli-responsive membrane for leukocyte enrichment and application thereof | TESKIN, FRED M | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18582695 | Thermo-induced stimuli-responsive membrane for leukocyte enrichment and application thereof | TESKIN, FRED M | 1632 | §102 | Non-Final OA | — | Pending | Feb 21, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFormosa Biomedical Material Technology Corporation has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Fred M Teskin has the most, with 1 of Formosa Biomedical Material Technology Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
